1Langholz E,Munkholm P,Davidsen M,et al.Course of ulcerative colitis:analysis of changes in disease activity over years.Gastroenterology,1994,107:3-11.
2Sandborn WJ.Current directions in IBD therapy:what goals are feasible with biological modifiers? Gastroenterology,2008,135:1442-1447.
3Faubion WA,Loftus EV,Harmsen WS,et al.The natural history of corticosteroid therapy for inflammatory bowel disease:a population-based study.Gastroenterology,2001,121:255-260.
4Ardizzone S,Maconi G,Russo A,et al.Randomized controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.Gut,2006,55:47-53.
5Froslie KF,Jahnsen J,Moum BA,et al.Mucosal healing in inflammatory bowel disease:results from a Norwegian population-based cohort.Gastroenterology,2007,133:412-422.
6Sandborn W,Rutgeerts P,Feagan BG,et al.Infliximab reduces colectomy in patients with moderate to severe ulcerative colitis:colectomy analysis ACT1 and ACT2.Gut,2007,56(suppl Ⅲ):A26.
7Rutgeerts P,Vermeire S,Van Assche G,et al.Mucosal healing in inflammatory bowel disease:impossible ideal or therapeutic target.Gut,2007,56:453-455.
7Ouyang Q, Tandon R, Goh KL, et al. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol, 2005,21:408-413.
8Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease : controversies, consensus, and implications. Gut, 2006, 55 : 749-753.
9Kornbluth A, Sachar D. Ulcerative colitis practice guidelines in adults (update). Am J Gastroenterol, 2004,99 : 1371-1385.
10Hanauer SB, Sandbom W, Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol, 2001,96: 635-643.
